The SMi Group will be holding a conference on Pharmaceutical Portfolio & Product Life Cycle Management from June 29-30, 2011 in London, UK. The conference will offer presentations on the following topics:• Linking portfolio management with business strategy;
• Portfolio management: Integrated approaches to R&D;
• Tailoring R&D portfolio management to the needs of your company;
• Project and portfolio risk analysis;
• Where is the strategy in the strategy?
• Holistic portfolio management at Bayer Healthcare Pharmaceuticals;
• Portfolio Management -- It’s not about the numbers;
• Managing a mixed portfolio: Making key decisions at the science, project, resource, and governance level;
• Partnerships, alliances and collaborations: Achieving successful portfolio management;
• In-house portfolio vs. in-licensing/out-licensing strategies (panel discussion);
• New approaches towards managing a portfolio of innovation projects;
• Creating and challenging LCM brand plans;
• Life-cycle management -- Applied case study;
• Life cycle management -- The academic spin-out contribution;
• Early stage strategies and intellectual property; and
• An update on data protection developments.
• Portfolio management: Integrated approaches to R&D;
• Tailoring R&D portfolio management to the needs of your company;
• Project and portfolio risk analysis;
• Where is the strategy in the strategy?
• Holistic portfolio management at Bayer Healthcare Pharmaceuticals;
• Portfolio Management -- It’s not about the numbers;
• Managing a mixed portfolio: Making key decisions at the science, project, resource, and governance level;
• Partnerships, alliances and collaborations: Achieving successful portfolio management;
• In-house portfolio vs. in-licensing/out-licensing strategies (panel discussion);
• New approaches towards managing a portfolio of innovation projects;
• Creating and challenging LCM brand plans;
• Life-cycle management -- Applied case study;
• Life cycle management -- The academic spin-out contribution;
• Early stage strategies and intellectual property; and
• An update on data protection developments.
No comments:
Post a Comment